Plain-English translation of NCT07360587 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing thyroid artery embolization (TAE)—a minimally invasive procedure that uses tiny tubes to reduce blood flow to an enlarged thyroid gland and shrink it. The procedure is being studied in people whose thyroid gland is causing problems like difficulty breathing or swallowing, but who either cannot have surgery or prefer to avoid it.
Many people with enlarged thyroid glands cannot have traditional surgery because of other health conditions or personal preference. This trial exists to prove that this procedure is a safe and effective option for those patients.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive thyroid artery embolization, a procedure in which a doctor guides a thin catheter through blood vessels to reach your thyroid gland and reduce its blood supply. The study will track your recovery and symptoms over a longer period to see how well the procedure works and whether it is safe.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Canada
Université de Sherbrooke
Enrollment target
~20 participants
Started
January 2026
Primary completion
December 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Laurent Fradet, MD FRCSC
Université de Sherbrooke
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.